Agenus to Host March 2026 Webcast on Advancing BOT+BAL Immunotherapy and Expanding Patient Access
Agenus , a biotechnology company at the forefront of immuno-oncology innovation, has announced that it will host its March 2026 Stakeholder Webcast, continuing its efforts to engage the scientific community, investors, and broader healthcare stakeholders. The upcoming session will focus on the company’s progress in advancing its combination immunotherapy program featuring botensilimab and balstilimab (commonly referred to as BOT+BAL), as well as updates on expanding patient access and strategic priorities for the year ahead.
The webcast represents a key milestone in Agenus’ ongoing Stakeholder Briefing Series for 2026. Building on insights shared during earlier sessions, this event is designed to provide a deeper understanding of how the company is leveraging the immune system to address unmet needs across a wide range of tumor types, particularly those that have historically demonstrated resistance to conventional immunotherapies.
The session will be moderated by Dr. Garo H. Armen, Founder, Chairman, and Chief Executive Officer of Agenus. Under his leadership, the company has pursued a mission centered on unlocking the full potential of immunotherapy by targeting complex cancer biology and improving outcomes for patients with limited treatment options. The webcast will conclude with a live question-and-answer segment, allowing participants to engage directly with company leadership and clinical experts.
A central theme of the webcast will be Agenus’ strategic direction in advancing the BOT+BAL program. Dr. Armen is expected to open the session by outlining the company’s overarching vision of harnessing the immune system to combat cancer across multiple tumor types. He will emphasize the urgency of developing innovative therapies for patients with cancers that have traditionally been difficult to treat, highlighting the growing momentum behind the BOT+BAL combination. Additionally, Dr. Armen will present key priorities for 2026, which include accelerating clinical development, expanding global reach, and strengthening the company’s position as a leader in next-generation immuno-oncology therapies.
The clinical progress of the BOT+BAL program will be another major focus of the webcast. Dr. Steven J. O’Day, Chief Medical Officer at Agenus, will provide a comprehensive overview of clinical data supporting the combination therapy. His discussion will center on the durability and consistency of treatment responses observed across different tumor types. Importantly, he will address how BOT+BAL is demonstrating activity even in cancers that have shown resistance to existing immunotherapies, a critical area of need in oncology.
Dr. O’Day will also highlight how emerging clinical data are guiding the design and execution of ongoing studies, including later-stage trials aimed at validating the efficacy and safety of the combination therapy. By examining both the breadth and depth of clinical responses, Agenus aims to establish BOT+BAL as a versatile treatment option capable of addressing diverse cancer indications. The insights shared during this segment are expected to underscore the scientific rationale behind the program and its potential to redefine treatment paradigms in immuno-oncology.
In addition to clinical advancements, the webcast will address Agenus’ efforts to expand patient access to its therapies. Dr. Kamel Djazouli, Head of Medical Affairs, will provide an update on the company’s global access initiatives. These programs are designed to ensure that patients with limited or no treatment options can benefit from investigational therapies while formal regulatory pathways are still being pursued.
Dr. Djazouli will discuss specific initiatives such as the French Autorisation d’Accès Compassionnel (AAC) program and Named Patient Programs in various regions. These pathways play a crucial role in bridging the gap between clinical development and widespread availability, allowing eligible patients to receive potentially life-saving treatments. He will also highlight how these programs are being implemented and scaled to reach more patients worldwide, reflecting Agenus’ commitment to equitable access and patient-centric care.
The stakeholder webcast will provide attendees with practical details to facilitate participation. Interested individuals can register through an online platform, after which they will receive access to the live webcast link. Agenus has also enabled an interactive component by allowing participants to submit questions in advance via a dedicated portal. This approach is intended to foster meaningful dialogue and ensure that key topics of interest are addressed during the session.
As the second installment in the 2026 Stakeholder Briefing Series, this webcast builds upon previous discussions that explored the clinical progress of the BOT+BAL program, as well as broader corporate milestones achieved by Agenus. By maintaining a consistent cadence of communication, the company aims to keep stakeholders informed about its evolving strategy and the impact of its innovations.
Overall, the March 2026 Stakeholder Webcast represents an important opportunity for Agenus to showcase its advancements in immunotherapy, particularly the promise of the BOT+BAL combination. Through detailed presentations from senior leadership and clinical experts, the session will provide valuable insights into how the company is addressing critical challenges in cancer treatment. It will also highlight Agenus’ commitment to expanding access to cutting-edge therapies and improving outcomes for patients around the world.
As the field of immuno-oncology continues to evolve, initiatives like this webcast play a vital role in fostering transparency, collaboration, and shared understanding among stakeholders. By bringing together scientific, clinical, and strategic perspectives, Agenus is positioning itself to drive meaningful progress in the fight against cancer and to deliver innovative solutions that meet the needs of patients and healthcare systems alike.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. Information that may be important to investors will be routinely posted on our website and social media channels.
About Botensilimab (BOT)
Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
